Novartis Ag

University of Pennsylvania

Engels, Boris

Li Zhou

Andreas Loew

Ming Lei

Jennifer Brogdon

David Jenkins

Carl H June

Saar Gill

Marco Ruella

Lu Huang

Jennifer Bordeaux

Jimin Zhang

Na Li

Thai Tran

Naveen Kumar Dakappagari

Ju Young Kim

Elena Orlando

Hans Bitter

Steven Highfill

Michael C Milone

David Jonathan Glass

Qilong Wu

Joan Mannick

Barbara Brannetti

Leon Murphy

Brian Edward Vash

Jan Weiler

Boris Engels

Brian Walter Granda

Huijuan Song

William Raj Sellers

John Hastewell

Seth Alexander Ettenberg

Feng Cong

Karen Vincent

Jennifer Mary Bordeaux

The invention provides compositions and methods for treating diseases associated with expression of CD19, e.g., by administering a recombinant T cell comprising the CD19 CAR as described herein, in combination with one or more B-cell inhibitors, e.g., inhibitors of one or more of CD10, CD20, CD22, CD34, CD123, FLT-3, ROR1, CD79b, CD179b, or CD79a. The disclosure additionally features novel antigen binding domains and CAR molecules directed to CD20 and CD22, and uses, e.g., as monotherapies or in combination therapies. The invention also provides kits and compositions described herein.

CD20 therapies, CD22 therapies, and combination therapies with a CD19 chimeric antigen receptor (CAR)-expressing cell

Compositions and methods relating to regulatable chimeric antigen receptors (RCARs), where the intracellular signaling or proliferation of the RCAR can be controlled to optimize the use of an RCAR-expressing cell to provide an immune response, are provided. For example, a RCAR can comprise a dimerization switch that, upon the presence of a dimerization molecule, can couple an intracellular signaling domain to an extracellular recognition element, e.g., an antigen binding domain, an inhibitory counter ligand binding domain, or costimulatory ECD domain. An RCAR can be engineered to include an appropriate antigen binding domain that is specific to a desired antigen target and used in the treatment of a disease.

Regulatable chimeric antigen receptor

The present invention relates to LRP6 constructs that bind to LRP6 receptor. The LRP6 constructs comprise at least one LRP6 binding moiety and a half-life extender molecule such that the LRP6 construct inhibit the Wnt signaling pathway without potentiation of the Wnt signal. The LRP6 constructs also have an increased half-life to provide more time for the therapeutic benefit.

Methods of treating cancer with low density lipoprotein-related protein 6 (LRP6)&#x2014;half life extender constructs

The present disclosure relates to an antibody or antigen binding fragment having at least two receptor binding domains for two different binding sites of LRP6 and compositions and methods of use thereof.

Therapeutic low density lipoprotein-related protein 6 (LRP6) multivalent antibodies

Low density lipoprotein-related protein 6 (LRP6)-half life extender constructs

Growing community of inventors

Cambridge, MA, United States of America

Li Zhou